AstraZeneca buys CDK9 portfolio

Share this article:

AstraZeneca has purchased the CDK9 portfolio of Germany-based Probiodrug AG. The Halle, Germany, biotech announced the deal Thursday, but did not disclose the price tag.

The agreement means AstraZeneca will now own the lead drug and back-up compounds associated with the molecule, which has an impact on genetic transcription connected to inflammation, a condition which is associated with cancer and inflammatory diseases.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.